What is the Fiscal Year for IGC Pharma?

Headquarters

Potomac, MD

Industry

Pharmaceutical Manufacturing

Stock Symbol

IGC

Website

Description

IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company focused on advancing innovative therapeutics and artificial intelligence solutions for Alzheimer's disease. Our research is driven by a commitment to addressing some of the greatest challenges in brain health through science, clinical innovation, and data-driven technologies. Our lead therapeutic candidate, IGC-AD1, is being evaluated in the Phase 2 CALMA clinical trial for the treatment of agitation associated with Alzheimer's disease. In parallel, we are developing AI-enabled platforms designed to accelerate Alzheimer's research by supporting data harmonization, predictive analytics, and scientific discovery. Beyond drug development, IGC Pharma is committed to advancing education and fostering meaningful conversations around Alzheimer's disease, neuroscience, and emerging healthcare technologies. Together, we are working toward a future where innovation improves the lives of patients, caregivers, and communities affected by Alzheimer's disease.